Cardio-vascular
Refine Search
Pharmaceutical
Norway's Serodus has entered into a license agreement with Swiss drug major Roche (ROG: VX) for a selective serotonin-4 (5-HT4) antagonist for the potential treatment of heart failure (RO1160367). Under the terms of the deal, Serodus will receive the full preclinical and clinical documentation for RO1160637. 14 December 2010
Biotechnology
Australia's Mesoblast (ASX: MSB) saw its shares rocket as much as to hit a higher of A$4.45, before closing up 21.65% at $4.05, after the biotechnology company revealed details of a deal with USA-based Cephalon (Nasdaq: CEPH) that could earn the firm in excess of $1.8 billion 9 December 2010
Pharmaceutical
Germany's Bayer Group (Bayer: DE) aims to invest its resources as a whole more consistently in growth and innovation capability. "We have a very successful record in innovation," said management board chairman Marijn Dekkers on Wednesday at "Bayer's Perspective on Innovation 2010" presentation in Leverkusen. "Our research and development spending will likely rise to a record 3.1 billion euros ($4.15 billion) in 2010 - an increase of 13%," he noted. However, he indicated that this level will not be raised for 2011, the first time there will be no rise since 2006. 9 December 2010
Generics
Haikou City-based China Pharma Holdings (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, says it has completed clinical trials of the cholesterol-lowering drug, rosuvastatin (a generic version of AstraZeneca's Crestor), which the company intends to commercialize in the large and expanding Chinese healthcare market. 7 December 2010
Pharmaceutical
Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced this morning that the European Commission has granted marketing authorization for its blockbuster potential oral blood thinning drug candidate Brilique (ticagrelor) for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS). 6 December 2010
Generics
US drugmaker Momenta Pharmaceuticals (Nasdaq: MNTA) announced that it has sued Israeli generics major Teva Pharmaceutical Industries in the US District Court for the District of Massachusetts for infringement of two Momenta patents. 3 December 2010
Pharmaceutical
New Zealand government drug funder PHARMAC will provide wider access to treatments for multiple sclerosis (MS), and fund new blood-thinning and antibiotic treatments following an agreement with the local subsidiary of German drug major Bayer (BAY: DE). 2 December 2010
Pharmaceutical
Amarin will apply for approval of cholesterol drug candidate AMR101 earlier on strong Ph III results
US/Irish biopharmaceutical firm Amarin (Nasdaq: AMRN), yesterday reported positive, statistically significant top-line results from the MARINE study, its first Phase III clinical trial of lead fish oil-based drug candidate AMR101, causing its stock to rocket 62% to $5.75 in early trading on Monday. 30 November 2010
Pharmaceutical
US generic drugmaker Impax Laboratories (Nasdaq: IPXL) confirmed that it has initiated a challenge of patents listed in connection with the cholesterol lowerer Simcor (niacin/simvastatin) extended-release tablets, 1000/20 mg. 29 November 2010
Pharmaceutical
According to a filing with the Hong Kong Stock Exchange, Sihuan Pharmaceutical, the second-largest cardio-cerebral vascular drugmaker in China, plans to acquire Dupromise Holdings for as much as 2.4 billion renminbi ($360.72 million), via its wholly-owned SunMoral International, reports China Knowledge Online. 29 November 2010
Pharmaceutical
As a result of drug side effects seen in the Phase III APPRAISE-2 clinical trial in patients with recent acute coronary syndrome (ACS) treated with the blood thinner apixaban or placebo in addition to mono or dual antiplatelet therapy, US drug majors Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) have discontinued the study for this indication. 22 November 2010
Pharmaceutical
Around a quarter of all heart attacks, strokes, and operations to open blocked arteries could be avoided in people with chronic kidney disease (CKD) by using the combination of ezetimibe and simvastatin, drug major Merck & Co's (NYSE: MRK) Vytorin, to lower blood cholesterol levels. That is the conclusion from the world's largest ever randomized trial in kidney disease. 22 November 2010
Pharmaceutical
Positive results from the Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study with US drug giant Merck & Co's (NYSE: MRK) investigational CETP [cholesteryl ester transfer protein] inhibitor] anacetrapib were presented at the American Heart Association meeting in Chicago, showing the drug significantly increased good cholesterol and lowering the bad. 18 November 2010
Pharmaceutical
German drug major Bayer (BAY: DE) yesterday announced the eagerly-awaited results from the pivotal, double-blind Phase III, ROCKET AF trial, which demonstrated that its Xarelto (rivaroxaban), under development with the USA's Johnson & Johnson (NYSE: JNJ) was superior to warfarin in reducing the risk of stroke and non-central nervous system systemic embolism in patients with atrial fibrillation (AF). 16 November 2010
Pharmaceutical
Findings from a new study show, compared to placebo, treatment with high-dose prescription omega-3 fatty acids did not reduce the recurrence of symptomatic atrial fibrillation (AF) among patients with symptomatic paroxysmal AF or persistent AF who have no evidence of substantial structural heart disease. The study was presented yesterday at the American Heart Association's Scientific Sessions and also published on-line in The Journal of the American Medical Association. 16 November 2010
Pharmaceutical
Studies presented at the American Heart Association conference taking place in Chicago, showed that people with mild heart failure lived longer and benefited from the addition of US drugs behemoth Pfizer's (NYSE: PFE) already marketed Inspra (eplerenone) to standard medications, a finding that could expand use of the drug in healthier patients. On a negative note, drug major Johnson & Johnson (NYSE: JNJ) and subsidiary Scios Natrecor (nesiritide) - also marketed ' revealed that the drug is safe for heart failure patients, although it offers few benefits. 15 November 2010
Generics
New Zealand's Pharmaceutical Management Agency (PHARMAC) has reached agreement with InterPharma Pty for seven oncology products and has also done a deal with Germany's Bayer (BAY: DE) for three products. 10 November 2010
Pharmaceutical
The discovery of a new gene variant by a European Union-funded research team opens the way to new prevention and treatment for high blood pressure (hypertension). One adult in four in the EU suffers from the condition which, as the most important cardiovascular risk factor, is ultimately the leading cause of death worldwide. 5 November 2010
Biotechnology
US biotech firm Biogen Idec (Nasdaq: BIIB), which recently report healthy third quarter 2010 results, also this week announced a round of cost cutting and restructuring aimed at annual savings of around $300 million. 4 November 2010
Pharmaceutical
As a result of generic erosion of key high-priced brands, the acute coronary syndrome drug market will decline from approximately $923 million in 2009 to $809 million in 2016 in the USA, France, Germany, Italy, Spain, UK and Japan, says a new report from research and advisory firm Decision Resources. Thereafter, the market will rise to $815 million by 2019 due to the launches and uptake of novel antithrombotic therapies. 3 November 2010
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze